← All candidates
One insider buy in the last year — $216.7K in all.
77 filings on record.
CLNNClene Inc.
NasdaqCM · Consumer Defensive · $45.87M
$3.57
+22.56% · Sep 15
One insider buy in the last year — $216.7K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 42 sells◆ 13 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what CLNN ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$45.87M
Float
9.8M
76% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
232.8
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Matlin David J
Bought $216.7K on Jan 13 — 33,333 sh @ $6.50, held direct, 7.0% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
48 more transactions on Pro →Context
Earnings · EPS vs forecast
1 of 4 quarters beat
Q2 '26−$0.48 act−$0.22
Q1 '26−$0.24 act+$0.46
Q4 '25−$0.78 act−$0.36
Q3 '25−$0.61 act−$0.05
Coverage
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker AnalysesMarketBeat · 3w agoClene Inc. (CLNN) Reports Q2 Loss, Beats Revenue EstimatesZacks · 08-14Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALSMarketBeat · 08-12Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks · 06-04
The file stays open
77 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice